Pierre R. Bonneau

2100 Cunard Street
Laval, H7S2G5, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Journal: ACS medicinal chemistry letters

Published: May 11, 2016

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Journal: Antimicrobial agents and chemotherapy

Published: March 26, 2014

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Journal: Journal of medicinal chemistry

Published: January 29, 2014

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Journal: ACS medicinal chemistry letters

Published: January 03, 2014

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Journal: Journal of medicinal chemistry

Published: August 08, 2013

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

Journal: Journal of medicinal chemistry

Published: June 19, 2013

Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

Journal: Journal of medicinal chemistry

Published: June 05, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

Journal: Acta crystallographica. Section D, Biological crystallography

Published: January 28, 2013

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

Journal: Journal of molecular biology

Published: January 18, 2013

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Journal: Bioorganic & medicinal chemistry letters

Published: August 27, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026